NCT04502472View on ClinicalTrials.gov

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

June 6, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Covid-19
Interventions
BIOLOGICAL

Convalescent plasma transfusion

Transfusion of COVID-19 convalescent plasma to participants currently hospitalized with COVID-19 infection with severe or life-threatening clinical syndrome.

Trial Locations (1)

22042

Inova Fairfax Medical Campus, Falls Church

Sponsors
All Listed Sponsors
lead

Inova Health Care Services

OTHER